Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hemagglutinin (HA) protein is a major surface glycoprotein of the influenza A virus, essential for viral entry into host cells. The H1 subtype refers to one of at least 18 known HA subtypes found in influenza A viruses. The HA protein is responsible for binding the virus to sialic acid-containing receptors on host cells and mediating fusion between the viral envelope and host cell membrane. It exists as a homotrimer, and its antigenic sites are targets for neutralizing antibodies. Mutations affecting receptor binding specificity or cleavability can enable cross-species transmission or increase virulence. H1 subtype has caused two major pandemics, underscoring its pandemic potential when new variants emerge.
Virus entry inhibition via hemagglutinin binding
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus hemagglutinin protein (H1 subtype) (None).